Moreno-Martos David, Verhamme Katia, Ostropolets Anna, Kostka Kristin, Duarte-Sales Talita, Prieto-Alhambra Daniel, Alshammari Thamir M, Alghoul Heba, Ahmed Waheed-Ul-Rahman, Blacketer Clair, DuVall Scott, Lai Lana, Matheny Michael, Nyberg Fredrik, Posada Jose, Rijnbeek Peter, Spotnitz Matthew, Sena Anthony, Shah Nigam, Suchard Marc, Chan You Seng, Hripcsak George, Ryan Patrick, Morales Daniel
Population Health and Genomics, University of Dundee, Dundee, UK.
Medical Informatics, Erasmus MC, Rotterdam, The Netherlands.
Wellcome Open Res. 2022 Mar 24;7:22. doi: 10.12688/wellcomeopenres.17403.2. eCollection 2022.
: Characterization studies of COVID-19 patients with chronic obstructive pulmonary disease (COPD) are limited in size and scope. The aim of the study is to provide a large-scale characterization of COVID-19 patients with COPD. : We included thirteen databases contributing data from January-June 2020 from North America (US), Europe and Asia. We defined two cohorts of patients with COVID-19 namely a 'diagnosed' and 'hospitalized' cohort. We followed patients from COVID-19 index date to 30 days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes among COPD patients with COVID-19. : The study included 934,778 patients in the diagnosed COVID-19 cohort and 177,201 in the hospitalized COVID-19 cohort. Observed COPD prevalence in the diagnosed cohort ranged from 3.8% (95%CI 3.5-4.1%) in French data to 22.7% (95%CI 22.4-23.0) in US data, and from 1.9% (95%CI 1.6-2.2) in South Korean to 44.0% (95%CI 43.1-45.0) in US data, in the hospitalized cohorts. COPD patients in the hospitalized cohort had greater comorbidity than those in the diagnosed cohort, including hypertension, heart disease, diabetes and obesity. Mortality was higher in COPD patients in the hospitalized cohort and ranged from 7.6% (95%CI 6.9-8.4) to 32.2% (95%CI 28.0-36.7) across databases. ARDS, acute renal failure, cardiac arrhythmia and sepsis were the most common outcomes among hospitalized COPD patients. : COPD patients with COVID-19 have high levels of COVID-19-associated comorbidities and poor COVID-19 outcomes. Further research is required to identify patients with COPD at high risk of worse outcomes.
对患有慢性阻塞性肺疾病（COPD）的新冠肺炎患者的特征研究在规模和范围上都很有限。本研究的目的是对患有COPD的新冠肺炎患者进行大规模特征描述。我们纳入了13个数据库，这些数据库提供了2020年1月至6月来自北美（美国）、欧洲和亚洲的数据。我们定义了两组新冠肺炎患者，即“确诊”组和“住院”组。我们对患者从新冠肺炎索引日期随访至30天或直至死亡。我们进行了描述性分析，并报告了患有COPD的新冠肺炎患者的特征和结局的频率。该研究在确诊的新冠肺炎队列中纳入了934,778名患者，在住院的新冠肺炎队列中纳入了177,201名患者。在确诊队列中观察到的COPD患病率，法国数据为3.8%（95%CI 3.5 - 4.1%），美国数据为22.7%（95%CI 22.4 - 23.0）；在住院队列中，韩国数据为1.9%（95%CI 1.6 - 2.2），美国数据为44.0%（95%CI 43.1 - 45.0）。住院队列中的COPD患者比确诊队列中的患者有更多的合并症，包括高血压、心脏病、糖尿病和肥胖。住院队列中的COPD患者死亡率更高，各数据库中的死亡率范围为7.6%（95%CI 6.9 - 8.4）至32.2%（95%CI 28.0 - 36.7）。急性呼吸窘迫综合征（ARDS）、急性肾衰竭、心律失常和脓毒症是住院的COPD患者中最常见的结局。患有COPD的新冠肺炎患者有高水平的与新冠肺炎相关的合并症且新冠肺炎结局较差。需要进一步研究以确定COPD患者中结局较差的高风险患者。
